PLx Opco Inc.

Address

8285 El Rio St Ste 130
Houston, TX, 77054-4654

http://www.plxpharma.com

Information

DUNS: 140243572
# of Employees: 9

Ownership Information

Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N

Award Charts




Award Listing

  1. Aspirin-PC for Chemoprevention of Colorectal Cancer

    Amount: $961,499.00

    ABSTRACT Colorectal cancer CRC is the third leading cause of cancer related deaths in the U S Based on numerous epidemiological studies and recent prospective clinical trials the use of daily aspi ...

    STTRPhase II2017Department of Health and Human Services National Institutes of Health
  2. Aspirin-PC for Chemoprevention of Colorectal Cancer

    Amount: $147,318.00

    DESCRIPTION (provided by applicant): Colorectal cancer is the third leading cause of cancer-related deaths in the U.S. Based on numerous epidemiological studies and recent prospective trials; the use ...

    STTRPhase I2013Department of Health and Human Services
  3. GI-Safer Formulation of Indomethacin for use in Preterm Neonates

    Amount: $1,118,398.00

    DESCRIPTION (provided by applicant): This application is for a SBIR Phase II grant. One of the major causes of morbidity and mortality of low birth weight neonates relates to injury, inflammation, per ...

    SBIRPhase II2012Department of Health and Human Services
  4. GI-Safer Formulation of Indomethacin for use in Preterm Neonates

    Amount: $157,934.00

    DESCRIPTION (provided by applicant): This application is a Phase I SBIR grant application. One of the major causes of morbidity and mortality of low birth weight neonates relates to injury, inflammati ...

    SBIRPhase I2010Department of Health and Human Services
  5. GI-Safer Naproxen Formulation RandD for the Treatment of Osteoarthritis and Related

    Amount: $745,708.00

    DESCRIPTION (provided by applicant): ABSTRACT: This application is a Phase I/Phase II Fast-Track SBIR application. Osteoarthritis (OA), the clinical syndrome of joint pain and dysfunction caused by jo ...

    SBIRPhase II2009Department of Health and Human Services
  6. PC-NSAIDs: Gastrointestinal-safe and potent anti-inflammatory drugs

    Amount: $729,992.00

    We have developed a novel class of phosphatidylcholine (PC)-associated nonsteroidal antiinflammatory drugs (NSAIDs) to treat inflammation and pain with reduced GI side-effects. In Phase I studies usin ...

    SBIRPhase II2008Army Department of Defense
  7. GI-Safer Naproxen Formulation RandD for the Treatment of Osteoarthritis and Related

    Amount: $263,605.00

    DESCRIPTION (provided by applicant): ABSTRACT: This application is a Phase I/Phase II Fast-Track SBIR application. Osteoarthritis (OA), the clinical syndrome of joint pain and dysfunction caused by jo ...

    SBIRPhase I2008Department of Health and Human Services
  8. GI safety and therapeutics of oil-based PC-NSAIDS

    Amount: $566,719.00

    DESCRIPTION (provided by applicant): In this Competing Continuation of our STTR Phase II grant, we propose to build upon the considerable progress made during the previous two funding cycles in our ef ...

    STTRPhase II2007Department of Health and Human Services
  9. PC-NSAIDs: Gastrointestinal-safe and potent anti-inflammatory drugs

    Amount: $117,392.00

    Contrasting in vitro and in vivo systems will be used to evaluate the anti-inflammatory/analgesic activity and side-effects of a family of phosphatidylcholine (PC) – associated NSAIDs. Previous stud ...

    SBIRPhase I2007Army Department of Defense
  10. GI safety and therapeutics of oil-based PC-NSAIDs

    Amount: $758,617.00

    DESCRIPTION (provided by applicant): In this Phase II application we propose to continue and expand the very promising line of experiments, performed during Phase I, to confirm the GI safety and thera ...

    SBIRPhase IIDepartment of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government